Cover Image
Market Research Report

Latin America, Middle East & Africa Companion Diagnostics Market (2019-2025)

Published by KBV Research Product code 911062
Published Content info 92 Pages
Delivery time: 1-2 business days
Price
Back to Top
Latin America, Middle East & Africa Companion Diagnostics Market (2019-2025)
Published: August 31, 2019 Content info: 92 Pages
Description

The Latin America, Middle East and Africa Companion Diagnostics Market would witness market growth of 20.7% CAGR during the forecast period (2019-2025).

Technological advances have introduced many modifications to the treatment approach against diseases. Companion diagnostics is associated with a growing need for improved personalized patient treatment that provides health care professionals and their patients a favorable outcome of treatment assurance, as opposed to traditional treatment methods. Companion diagnostics will also have a major effect on the area of oncology therapy.

The development of the companion diagnostics industry will be stepping up with increasing cases of adverse drug reaction (ADR). Due to the incompatibility of certain patients with conventional treatment, adverse drug reactions occur and may cause life-threatening results. However, elevated costs of companion diagnostics can to some extent hinder business growth.

Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.

Scope of the Study

Market Segmentation:

By Technology

  • Immunohistochemistry
  • Polymerase chain reaction (PCR)
  • Next generation sequencing (NGS)
  • In Situ Hybridization and
  • Other Technology

By Indication

  • Oncology
  • Neurology and
  • Other Indications

By Cancer Type

  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Blood Cancer and
  • Other Cancer Type

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled:

  • Agilent Technologies, Inc.
  • Almac Group
  • ARUP Laboratories, Inc.
  • Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Hologic, Inc.
  • Novartis AG
  • Illumina, Inc.
  • Qiagen N.V.

Unique Offerings from KBV Research:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Companion Diagnostics Market, by Technology
    • 1.4.2 LAMEA Companion Diagnostics Market, by Indication
    • 1.4.3 LAMEA Companion Diagnostics Market, by Cancer Type
    • 1.4.4 LAMEA Companion Diagnostics Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Executive Summary
    • 2.1.3 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. LAMEA Companion Diagnostics Market by Technology

  • 3.1 LAMEA Immunohistochemistry Market by Country
  • 3.2 LAMEA Polymerase chain reaction (PCR) Market by Country
  • 3.3 LAMEA Next generation sequencing (NGS) Market by Country
  • 3.4 LAMEA In Situ Hybridization Market by Country
  • 3.5 LAMEA Other Technology Market by Country

Chapter 4. LAMEA Companion Diagnostics Market by Indication

  • 4.1 LAMEA Oncology Companion Diagnostics Market by Country
    • 4.1.1 LAMEA Companion Diagnostics Market by Cancer Type
      • 4.1.1.1 LAMEA Breast Cancer Companion Diagnostics by Country
      • 4.1.1.2 LAMEA Colorectal Cancer Companion Diagnostics by Country
      • 4.1.1.3 LAMEA Lung Cancer Companion Diagnostics by Country
      • 4.1.1.4 LAMEA Blood Cancer Companion Diagnostics by Country
      • 4.1.1.5 LAMEA Other Cancer Type Companion Diagnostics Market by Country
  • 4.2 LAMEA Neurology Companion Diagnostics Market by Country
  • 4.3 LAMEA Other Indications Companion Diagnostics Market by Country

Chapter 5. LAMEA Companion Diagnostics Market by Country

  • 5.1 Brazil Companion Diagnostics Market
    • 5.1.1 Brazil Companion Diagnostics Market by Technology
    • 5.1.2 Brazil Companion Diagnostics Market by Indication
      • 5.1.2.1 Brazil Companion Diagnostics Market by Cancer Type
  • 5.2 Argentina Companion Diagnostics Market
    • 5.2.1 Argentina Companion Diagnostics Market by Technology
    • 5.2.2 Argentina Companion Diagnostics Market by Indication
      • 5.2.2.1 Argentina Companion Diagnostics Market by Cancer Type
  • 5.3 UAE Companion Diagnostics Market
    • 5.3.1 UAE Companion Diagnostics Market by Technology
    • 5.3.2 UAE Companion Diagnostics Market by Indication
      • 5.3.2.1 UAE Companion Diagnostics Market by Cancer Type
  • 5.4 Saudi Arabia Companion Diagnostics Market
    • 5.4.1 Saudi Arabia Companion Diagnostics Market by Technology
    • 5.4.2 Saudi Arabia Companion Diagnostics Market by Indication
      • 5.4.2.1 Saudi Arabia Companion Diagnostics Market by Cancer Type
  • 5.5 South Africa Companion Diagnostics Market
    • 5.5.1 South Africa Companion Diagnostics Market by Technology
    • 5.5.2 South Africa Companion Diagnostics Market by Indication
      • 5.5.2.1 South Africa Companion Diagnostics Market by Cancer Type
  • 5.6 Nigeria Companion Diagnostics Market
    • 5.6.1 Nigeria Companion Diagnostics Market by Technology
    • 5.6.2 Nigeria Companion Diagnostics Market by Indication
      • 5.6.2.1 Nigeria Companion Diagnostics Market by Cancer Type
  • 5.7 Rest of LAMEA Companion Diagnostics Market
    • 5.7.1 Rest of LAMEA Companion Diagnostics Market by Technology
    • 5.7.2 Rest of LAMEA Companion Diagnostics Market by Indication
      • 5.7.2.1 Rest of LAMEA Companion Diagnostics Market by Cancer Type

Chapter 6. Company Profiles

  • 6.1 Agilent Technologies, Inc.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 Recent strategies and developments:
      • 6.1.5.1 Product launches:
      • 6.1.5.2 Expansions:
  • 6.2 Almac Group
    • 6.2.1 Company Overview
    • 6.2.1 Recent strategies and developments:
      • 6.2.1.1 Collaborations, partnerships and agreements:
  • 6.3 ARUP Laboratories, Inc.
    • 6.3.1 Company Overview
  • 6.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Segmental and Regional Analysis
    • 6.4.4 Research & Development Expense
  • 6.5 Danaher Corporation
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental and Regional Analysis
    • 6.5.4 Research & Development Expense
    • 6.5.5 Recent strategies and developments:
      • 6.5.5.1 Acquisition and mergers:
  • 6.6 Thermo Fischer Scientific, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
    • 6.6.5 Recent strategies and developments:
      • 6.6.5.1 Collaborations, partnerships and agreements:
      • 6.6.5.2 Expansions:
  • 6.7 Hologic, Inc.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Segmental and Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Product launches:
      • 6.7.5.2 Acquisition and mergers:
  • 6.8 Novartis AG
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Segmental and Regional Analysis
    • 6.8.4 Research & Development Expense
    • 6.8.5 Recent strategies and developments:
      • 6.8.5.1 Collaborations, partnerships and agreements:
  • 6.9 Illumina, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Product launches:
      • 6.9.5.2 Acquisition and mergers:
      • 6.9.5.3 Collaborations, partnerships and agreements:
  • 6.1 Qiagen N.V.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Regional Analysis
    • 6.10.4 Research & Development Expense
    • 6.10.5 Recent strategies and developments:
      • 6.10.5.1 Product launches:
      • 6.10.5.2 Collaborations, partnerships and agreements:

LIST OF TABLES

  • TABLE 1 LAMEA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 2 LAMEA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 3 LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 4 LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 5 LAMEA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 6 LAMEA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 7 LAMEA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 8 LAMEA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 9 LAMEA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 10 LAMEA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 11 LAMEA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 12 LAMEA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 13 LAMEA OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 14 LAMEA OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 15 LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 16 LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 17 LAMEA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 18 LAMEA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 19 LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 20 LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 21 LAMEA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 22 LAMEA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 23 LAMEA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 24 LAMEA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 25 LAMEA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 26 LAMEA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 27 LAMEA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 28 LAMEA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 29 LAMEA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 30 LAMEA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 31 LAMEA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 32 LAMEA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 33 LAMEA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 34 LAMEA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 35 LAMEA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 36 LAMEA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 37 BRAZIL COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 38 BRAZIL COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 39 BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 40 BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 41 BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 42 BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 43 BRAZIL COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 44 BRAZIL COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 45 ARGENTINA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 46 ARGENTINA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 47 ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 48 ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 49 ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 50 ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 51 ARGENTINA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 52 ARGENTINA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 53 UAE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 54 UAE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 55 UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 56 UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 57 UAE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 58 UAE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 59 UAE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 60 UAE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 61 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 62 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 63 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 64 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 65 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 66 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 67 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 68 SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 69 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 70 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 71 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 72 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 73 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 74 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 75 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 76 SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 77 NIGERIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 78 NIGERIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 79 NIGERIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 80 NIGERIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 81 NIGERIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 82 NIGERIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 83 NIGERIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 84 NIGERIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 85 REST OF LAMEA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 86 REST OF LAMEA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 87 REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 88 REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 89 REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 90 REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 91 REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 92 REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 93 KEY INFORMATION - AGILENT TECHNOLOGIES, INC.
  • TABLE 94 KEY INFORMATION - ALMAC GROUP
  • TABLE 95 KEY INFORMATION - ARUP LABORATORIES, INC.
  • TABLE 96 KEY INFORMATION - ABBOTT LABORATORIES
  • TABLE 97 KEY INFORMATION - DANAHER CORPORATION
  • TABLE 98 KEY INFORMATION - THERMO FISHER SCIENTIFIC, INC.
  • TABLE 99 KEY INFORMATION - HOLOGIC, INC.
  • TABLE 100 KEY INFORMATION - NOVARTIS AG
  • TABLE 101 KEY INFORMATION - ILLUMINA, INC.
  • TABLE 102 KEY INFORMATION - QIAGEN N.V.

LIST OF FIGURES

  • FIG 1 METHODOLOGY FOR THE RESEARCH
Back to Top